Rethink it: Digital is not a thing, digital is a means

In this episode of the Driving Digital in Biopharma podcast, Samer Ansari, Head of Data, Digital, and Technology at Takeda Oncology, joins Tom Lehmann, Global Head of Accenture Life Sciences R&D, to discuss the role of digital in creating exceptional HCP and patient experiences. Through their shared passion for data and tech and the importance of using it to positively change not only the Life Sciences industry but also the lives of our loved ones, Samer and Tom explore how Takeda is leveraging data to create a meaningful impact on patients’ experiences. We glimpse into the actions Samer and his team are taking around the globe, discuss how their organizational structure and innovation mindset create the opportunity for agility, and explore real-life applications of technology to improve patient outcomes. Samer emphasizes the need to balance investment choices with business expectations and ultimately showcase the impact of those investments, while always keeping the patient at heart. 

In this episode of Driving Digital in Biopharma, Accenture host, Tom Lehmann, speaks to Chris Braithwaite, Global Head of Drug Development, Digital and IT Novartis. Achieving digital transformation requires a delicate balance between traditional methods, rapidly emerging technology, and human decision-making. Chris encourages a shift in perspective and a focus on change management, emphasizing that working in a human+machine mode does not entail eliminating human roles. Instead, it involves developing comfort and knowledge regarding data and technology to enhance human potential and increase role effectiveness. By embracing digital tools and leveraging data, organizations can empower themselves to make informed decisions, drive adoption, and ultimately improve patient care.

In this episode of Driving Digital in Biopharma, Accenture host, Tom Lehmann, talks with Michel Rider, VP Digital, Analytics and Performance at GSK. Michel reflects on their multi-year quest to modernize digital, data, and analytics capabilities across Development – sharing insights for achieving near-term wins while planning for the future. There is a sense of urgency for patients seeking better, faster treatments. And this is a non-linear endeavor – iteration and evolution are a given. A compressed transformation approach combined with agile experimentation can deliver tangible benefits quickly and establish a foundation for future growth.

In this episode of Driving Digital in Biopharma, host Tom Lehmann talks with Jason Bronfeld, Head of Product Development IT at Bristol-Myers Squibb, about the industry re-perceiving itself and capitalizing on the power of digital.  When it comes to evolving ways of operating to an ever-better model for the future, a mindset shift is essential – digital is a means and not the end. The biopharma industry is viewed as knowledge-generating enterprises, and while ever-growing amounts of data present complex challenges, a strong digital core will fuel competitive advantages.

In this episode, Tom Lehmann talks with Natasha Kelly, a data scientist within Accenture's Applied Intelligence Group who focuses on advanced analytic solutions in life sciences manufacturing and supply chain. Tom and Natasha discuss the 2022 Life Sciences Technology Vision through a supply chain lens, delving into how each of the report's four trends ingrained in the metaverse are reshaping supply chain and operations experiences across the industry.

In this episode, Tom Lehmann talks with Accenture’s Ross Wooddisse, Managing Director and Life Sciences R&D Lead in Europe, about the 2022 Life Sciences Technology Vision and what the Metaverse continuum means for Biopharma R&D. They discuss how science turns into medicine, a new generation of digital trial capabilities and the fundamental opportunity for the industry to move from disease management towards risk prediction and disease prevention.

In this episode Tom Lehmann talks with Shalu Chada, Managing Director and Accenture’s Life Sciences Technology Lead, to discuss the 2022 Life Sciences Technology Vision and how each of the report's four trends ingrained in the metaverse are reshaping biopharma experiences of the future.

In this episode of Driving Digital in Biopharma, host Tom Lehmann talks with Anders Persson – Executive Director, Ecosystem Strategy & Innovation, AstraZeneca, about the role of digital and data in the transformation of global drug development and the value of an ecosystem and partnership strategy in R&D.

Tom Lehmann and Eddie Reilly, Chief regulatory officer and head of global regulatory affairs, Sanofi discuss delivering new therapies to patients more efficiently and how that’s enabled by regulatory affairs - from standardizing data and harnessing AI to the more proficiently exchanging data with health authorities.

Host Tom Lehmann talks with Lars Fogh Iversen, Senior Vice Present for Digital Science & Innovation at Novo Nordisk. They discuss the journey to accelerate research and early development through laboratory automation, data management, AI and digital research.